Eledon Pharmaceuticals, Inc.
- Jurisdiction
United States - LEI
549300S17CAM13O43606 - ISIN
US28617K1016 (ELDN )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Read full profile
Stock price
Fundamentals
- Net revenue
€163.77K - Gross margin
100.0% - EBIT
-€74.81M - EBIT margin
-45,682.8% - Net income
€12.49M - Net margin
7,626.6%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
| N/A |
| |
| N/A |
| |
|
|
|
Dividends
No dividend payouts
Earnings Calls
Latest earnings call: May 12, 2023
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Sell |